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Abstract
The endoplasmic reticulum (ER) provides a specialized environment for the folding and modification of trans-
membrane proteins, including receptor tyrosine kinases (RTKs), which are vital for the growth and survival of
malignancies. To identify compounds which disrupt the function of the ER and thus could potentially impair cancer
cell survival signaling, we adapted a set of glycosylation-sensitive luciferase reporters for the development and
optimization of a cell-based high-throughput screen (HTS). Secondary screens for false-positive luciferase activation
and tertiary lectin-based and biochemical analyses were also devised for compound triage. Through a pilot screen of
2802 compounds from the National Cancer Institute (NCI) chemical libraries, we identified aclacinomycin (Acm) as a
compound that preferentially affects ER function. We report that Acm reduces plasma membrane expression of
glycoproteins including epidermal growth factor receptor (EGFR) andMet but does not inhibit N-linked glycosylation
or generalized protein translation. Fluorescence microscopy co-localization experiments were also performed and
demonstrated Acm accumulation in the ER in further support of the overall HTS design. The consequences of Acm
treatment on cell survival were analyzed through clonogenic survival analysis. Consistent with the reduction of
EGFR levels, pretreatment with Acm sensitizes the EGFR-mutant non–small cell lung cancer (NSCLC) cell lines
HCC827 and HCC2935 to ionizing radiation and did not affect the sensitivity of the RTK-independent and KRAS-
mutant A549 NSCLC cell line. Thus, Acm and similar compounds targeting the ER may represent a novel approach
for radiosensitizing tumor cells dependent on RTK function.
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Introduction
The endoplasmic reticulum (ER) is a multifunctional eukaryotic
organelle. The ER’s main functions are to guide the proper folding
and sorting of transmembrane and secretory proteins through a set of
specialized ER-resident chaperones and biosynthetic pathways. To
accomplish this, the ER provides a highly oxidative environment
to allow for formation of disulfide bonds, is the subcellular site of
N-glycosylation to aid in tertiary structure adoption and protein
sorting, and contains internal quality control mechanisms to insure
proper protein folding [1]. Compounds that disrupt the function of
the ER, such as the N-glycosylation inhibitor tunicamycin (Tn) or the
Ca++ ATPase inhibitor thapsigargin, are known to interfere with pro-
tein function through interruption of these processes and induction
of the unfolded protein response, an ER-dependent stress response
intended to restore protein folding and normalize cell function [2,3].
One key family of proteins that is exceptionally dependent on the
function of the ER is the receptor tyrosine kinase (RTK) family.
RTKs are conserved, multifunctional transmembrane proteins that
are proto-oncogenes and both cause transformation and promote
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growth of malignant tumors [4]. RTKs adapt their tertiary structures
with the assistance of ER-resident chaperones, are N-glycosylated by
the ER-resident oligosaccharyltransferase complex, and are stabilized
by disulfide bonds catalyzed in the ER. RTKs that adapt the proper
structure are allowed to continue on to the Golgi apparatus for fur-
ther modification [5,6] and eventually to the plasma membrane where
they can respond to their ligands and elicit the appropriate cellu-
lar responses.
Because of their importance to cell signaling and well-established
role in malignancies, RTKs are attractive therapeutic targets. The epi-
dermal growth factor receptor (EGFR), a member of the ErbB RTK
family, is a salient example and is overexpressed in head and neck
squamous cell carcinomas [7], amplified with an oncogenic extracel-
lular domain deletion in malignant gliomas [8], and amplified with
oncogenic kinase domain mutations in lung adenocarcinomas [9].
For head and neck squamous cell carcinomas and EGFR kinase
domain mutant lung adenocarcinoma, EGFR-targeted therapies
either with or without radiation therapy have been demonstrated
to improve patient outcomes in randomized trials [10,11].
However, a limitation to therapeutic agents that inhibit individual
RTKs is that tumors activate parallel signaling pathways, such as Met
or ErbB3 following EGFR inhibition [12,13], or alternatively acquire
resistance to these inhibitors through mutation (such as the resistant
EGFRT790M), and thus circumvent inhibition of the targeted receptor
[14]. Due to these compensatory mechanisms and cooperative signaling
between RTK pathways [15,16], the inhibition of multiple targets may
be necessary to fully disable receptor-mediated survival signaling. We
have previously demonstrated that inhibition of N-linked glycosylation
is one ER-directed approach to reduce signaling from multiple co-
expressed RTKs and we have used this strategy to sensitize tumor cells
to ionizing radiation [17,18]. To further explore this therapeutic con-
cept, we sought to identify small molecules that interfere with ER
homeostasis and consequently impair the survival signaling initiated
by RTKs. We now report on the development of a bioluminescent
cell-based high-throughput screen (HTS) designed to identify com-
pounds that preferentially disrupt ER function.Our results demonstrate
the proficiency of this screening approach and identify aclacinomycin
(Acm), a compound with previously unrecognized effects on the ER,
which can be used to radiosensitize EGFR-addicted cell models.
Materials and Methods
Reagents
Cell culture reagents and ER-Tracker Blue-White DPX dye were
obtained from Gibco/Life Technologies (Carlsbad, CA). The anti-
EGFR antibody was a gift from J. Schlessinger (Yale University, New
Haven, CT). The c-Met antibody was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Antibodies recognizing Grp78 and
HSP70 were obtained from Cell Signaling Technologies (Danvers,
MA). Acm was obtained from the National Cancer Institute (NCI)
Developmental Therapeutics Program (NCI No. 208734). Tn, con-
canavalin A (Con A), and swainsonine (Sw) were purchased from
Calbiochem/Merck (Rockland, MA). Protease inhibitor tablets were
purchased from Roche (Basel, Switzerland), and phosphatase inhibitor
cocktails were purchased from Sigma (St Louis, MO). All Western
blot analysis supplies were obtained from Bio-Rad (Hercules, CA).
The ONE-Glo Luciferase Assay (No. E6120) and MTS Assay kits
(No. G4000) were purchased from Promega (Madison, WI).
Cell Lines
D54-ERLucT and D54-LucT cells were generated by Lipofectamine
(Life Technologies) transfection of vectors containing either the control
luciferase gene or a luciferase gene preceded by an ER translation
sequence. Clones with luciferase expression were isolated by serial
dilution and selection with 0.5 μg/ml G418 [18]. CHO and Lec-15
cells were a gift fromMark Lehrman (University of Texas Southwestern,
Dallas, TX) and, unless otherwise indicated, grown and maintained in
Ham’s F-12 media supplemented with 10% FBS and penicillin and
streptomycin. HCC2935, HCC827, and A549 cell lines were obtained
from the American Type Culture Collection (ATCC, Rockville, MD).
Unless otherwise indicated, human cells were kept in a 37°C incubator
with 5% CO2 and grown as monolayers in RPMI 1640 + 10% FBS
supplemented with penicillin and streptomycin.
High-throughput Bioluminescent Screens
Screen optimization. For the DMSO dose-response experiment,
five serial 1:2 dilutions of DMSO in growth medium starting at a
top concentration of 0.3% DMSO were added in eight replicates to
D54-ERLucT cells in an opaque white 96-well plate by a multichannel
pipette. For HTS cell titer optimization, a range of D54-ERLucT cells
(5 × 102 to 5 × 103 per well) were plated in 20 μl of growth medium in
opaque white 384-well plates and allowed to attach overnight. Each
384-well plate reserved 16 wells each for positive (1 μM Tn) and
negative controls (0.1% DMSO). The following day, Tn and DMSO
were added by a 20-nl pin tool and plates were returned to the incu-
bator for 48 hours. For the Tn dose-response experiment, 15 serial 1:2
dilutions of Tn starting at a top concentration of 30 μM were added
in eight replicates to growing D54-ERLucT cells by a multichannel
pipette and the 10 μM positive control was omitted. To quantify lumi-
nescence for the optimization experiments, one plating volume (100 μl
for 96-well plates or 20 μl for 384-well plates) of ONE-Glo luciferase
assay reagent (Promega) was added to each well, then plates were mixed
and incubated for 5 minutes at room temperature, and counts per sec-
ond were read in a luminescence-equipped multiplate reader (BioTek
Synergy HT). Data were represented as relative light unit (RLU) or as
fold increase RLU over DMSO-only controls for each experiment.
Bioluminescent screening. D54-ERLucT cells (3 × 103) were plated
in 100 μl of RPMI 1640 + 10% FBS (HyClone) supplemented
with penicillin and streptomycin in opaque 384-well plates and allowed
to attach overnight. The following day, 2802 compounds from the
NCI Diversity Set II, Mechanistic Set, and Natural Products libraries
were added using pin tool and incubated for 24 hours. Each plate
containedTn andDMSOas positive and negative controls, respectively.
Luminescence values were read using a FloStar Optima multiplate
reader (BMGLabtech, Ortenberg, Germany) and converted from RLU
to “percent effect” by the formula %E = [(observed RLU − negative
control RLU)/(positive control RLU − negative control RLU)]. For
the secondary screen, 3 × 103 D54-LucT cells were plated in 100 μl
of RPMI 1640 + 10% FBS supplemented with penicillin and strepto-
mycin in opaque 96-well plates and allowed to attach overnight. The
following day, hit compounds from the primary screen were added us-
ing multichannel pipette and incubated for 24 hours. Luminescence
values were read using a multiplate reader (BioTek Synergy HT). A
ratio of the fold increase RLU in the primary screen to the increase
in RLU in the secondary screen was generated for each hit compound.
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Western Blot Analysis
Cells were washed with 1× phosphate-buffered saline (PBS) and
harvested on ice. Lysates were prepared in Western lysis buffer as pre-
viously described [17] (25 mM Tris, 10 mM EDTA, 15% glycerol,
0.1% Triton X-100, 1× protease inhibitor cocktail, and 1× phospha-
tase inhibitor cocktails 2 and 3) by repeatedly passing cells through a
22-gauge syringe needle. Lysates were quantified using a Bradford
protein assay (Bio-Rad) and equal protein amounts were subjected
to polyacrylamide gel electrophoresis.
In Vitro Luciferase Assays
CHO cells with the ERLucT reporter were grown to confluence in
15-cm dishes and lysed in 2 ml of freshly prepared lysis buffer [20 mM
Tris-Cl (pH 7.5), 10 mM NaCl, 1 mM DTT, 15 mM MgSO4, and
0.1%NP-40] by vortexing. Lysates were centrifuged at 15,000 rpm for
5 minutes in a desktop centrifuge at 4°C and placed on ice. Lysates were
then incubated with drug or control compounds for 5 minutes at room
temperature, and then added to 12 × 75 mM tubes containing 100 μl
of pre-aliquoted 1× Luc assay buffer [20 mMTris-Cl (pH 7.5), 10 mM
NaCl, 1 mM DTT, 15 mMMgSO4, 2 mM ATP, and 500 μM lucif-
erin] and read immediately in a single-read luminometer (EG&G
Berthold Lumat 9507B) with a 10-second flash read. Linear range
for the luminometer was determined by diluting a control luciferase-
containing lysate.
Lectin Selection Assays
Positive growth selection after Con A treatment was performed in
96-well plates seeded with 1 × 103 D54 cells per well. The day after
plating, Acm (25 or 10 nM), Sw (2 μg/ml), or Con A (12.5 μg/ml) was
added as indicated. Cells were then grown for 72 hours and assayed by
tetrazolium reduction (MTS; Promega) and quantified using a multi-
plate reader set to read absorbance at 490 nM, and values were normal-
ized to vehicle-only controls.
Lipid-linked Oligosaccharide Extraction and
Fluorophore-Assisted Carbohydrate Electrophoresis
Lipid-linked oligosaccharides (LLOs) were extracted essentially as
described [19,20]. Briefly, adherent cells were pretreated with 10 μM
Acm for 6 hours, washed with cold 1× PBS, and scraped into cold 1×
PBS and pelleted at 500g for 5 minutes. The cell pellet was washed
twice with 4°C PBS and then resuspended in 1 ml of 4°C methanol.
The methanol suspension was evaporated to near dryness under a
vacuum using a SpeedVac (Thermo Fisher Savant SC100) modified to
accept 15-ml centrifuge tubes. The near-dry pellet was resuspended in
0.9ml of water and sonicated for 2minutes with 1-second on-off pulses.
Methanol (1.5 ml) was added to the aqueous cell suspension and this
mixture was vortexed for 30 seconds and sonicated again. Chloroform
(3ml) was added to thismixture, vortexed for 1minute, and centrifuged
at 3000g for 10minutes to resolve three phases (organic, aqueous, and a
middle LLO-containing phase). LLOs were collected and resuspended
in 3ml of a freshly preparedmixture of chloroform,methanol, andwater
(10:10:3), centrifuged at 3000g for 10minutes, and the entire solute was
dried under a vacuum. LLOswere extracted from this pellet bymild acid
hydrolysis; the pellet was resuspended in 80% tetrahydrofuran, 37%
hydrochloric acid was added to a final concentration of 0.1 M, and
the tubes were placed in a 50°C water bath for 90 minutes. After hydro-
lysis, the tetrahydrofuran (THF)/HCl mixture was dried completely
under vacuum, and the pellet was resuspended in 400 μl of water and
1ml of a freshly preparedmixture of chloroform andmethanol (2:1) was
added. This suspension was vortexed and spun at 3000g for 10 minutes
to resolve two phases; the aqueous phase was dried under vacuum for la-
beling and gel analysis. LLOs were labeled with 8-aminonaphthalene-
1,3,6-trisulfonic acid using a commercially available labeling kit (Prozyme
No. GK50004), resolved by electrophoresis through oligosaccharide pro-
filing gels (Prozyme No. GK60020), and observed using a UV gel doc
system (Syngene G:BOX) fitted with a digital camera and 302/365 nm
UV converter plate (VWR No. 95025-406).
Microscopy
Localization of Acm and the ER was accomplished in live
HCC2935 or HCC827 cells grown in 6-cm dishes and treated with
10 μM Acm for 24 hours before visualization. Plates were washed
once with 1× Hank’s balanced salt solution (HBSS) and then incu-
bated with 1 μM ER-Tracker Blue-White DPX dye in 1× HBSS for
15 minutes. Cells were rinsed once more with 1× HBSS to remove
unbound dye and kept in HBSS without dye for observation. Cells
were observed without fixation using equivalent exposure settings
and a 470/525 nM filter (Acm) or a wide-pass DAPI filter (ER Tracker)
using an EVOS-FL digital inverted microscope equipped with mono-
chrome camera and a 40× objective (AMG, Bothell, WA). Images for
two-channel merges were created by the built-in microscope software.
Clonogenic Survival Assays
Clonogenic survival assays were performed by standard methods
in triplicate wells using six-well plates. Growing cells were pretreated
in 10-cm tissue culture plates with 500 nM Acm A for 2 hours, then
washed, trypsinized, and replated in triplicate wells using six-well
plates. Six-well plates were treated with a single dose of either 0 (con-
trol), 2, 4, or 6 Gy at approximately 2 Gy/45 seconds in a Precision
X-ray 320-kV orthovoltage unit. Cells were grown for 14 (A549) or
21 days (HCC2935 and HCC827) to produce colonies of >50 cells/
colony, washed once with 1× PBS, then stained with 0.25% crystal
violet in 80% methanol.
Data Analysis
Data are plotted as experimental mean ± SEM. Statistical signifi-
cance was determined as P < .05 using a two-tailed Student’s t test.
The Z factor for high-throughput experiments was calculated as de-
scribed [21]: Z ′ = [1 − (3(σρ + ση)/(μρ − μη))], where ρ and η represent
the positive and negative controls.
Results
HTS Optimization
To directly monitor posttranslational processes in the ER of living
cells, we have developed a functional bioluminescent reporter vector,
ERLucT (Figure 1A), which targets the Photinus pyralis luciferase
gene for ER translation through in-frame addition of the EGFR
N-terminal amino acid leader sequence. Previously, we have detailed
incorporation of Asn-X-Ser/Thr glycosylation consensus sites into
the luciferase coding sequence to produce a highly sensitive molecu-
lar imaging strategy for dynamically measuring aspargine (N)–linked
glycosylation in vivo [17,18]. Under normal cell growth conditions,
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the reporter is translated into the ER and glycosylated, inactivating the
enzymatic activity of luciferase. However, under conditions where the
reporter does not undergo glycosylation or glycosylation is insufficient
to block enzymatic activity, functional changes in the ER compartment
can be measured through an increase in bioluminescence. A second
identical luciferase gene lacking the ER translation signal (LucT) is used
as a control vector for nonspecific luciferase activation because it cannot
be modified by ER-resident glycosylation machinery.
We hypothesized that the ERLucT/LucT reporter system could be
optimized as anHTS to identify compounds that preferentially disrupt
biologic processes of the ER such as N-linked glycosylation (NLG).
Using D54 glioma cells with stable expression of ERLucT, we exper-
imentally established conditions for HTS in 96-well and 384-well
plate formats and used Tn, a GlcNAc-phosphotransferase inhibitor,
as a positive control. First, the effects of DMSO on reporter function
were determined to quantitate potential effects on assay performance,
as this vehicle is used to solubilize compounds in chemical libraries.
We found that DMSO concentrations do not cause significant in-
creases in luminescence in the D54-ERLucT line at assay relevant con-
centrations, although a 1.5 ± 0.1-fold increase was observed at 0.3%
DMSO (Figure 1B). To avoid this minimal effect, DMSO was kept
at or below a final concentration of 0.1% for all experiments. Next, we
evaluated the effects of cell plating density and found similar levels of
Tn-induced reporter activity. To increase signal differences between
positive and negative controls, a cell titer of 3000 cells per well was used
for all subsequent experiments (Figure 1C). Dose-response experiments
with the positive control, Tn, were then performed (Figure 1D) and
demonstrated an 8.0 ± 0.1-fold peak induction of luciferase activity
over control cells. The half-maximal effective concentration of Tn using
this reporter is 40.3 ± 1.0 nM. The mean Z factor for positive and
negative controls was calculated to be 0.71 (SD ± 0.04).
HTS Identifies Acm as a Preferential ERLucT Activator
Using this live cell bioluminescent assay, we performed an HTS to
find compounds that preferentially activate the ERLucT reporter and to
identify small molecules that interfere with biologic functions of the
ER. Two thousand eight hundred and two compounds from the NCI
Diversity Set, Mechanistic Set, and Natural Products libraries were
screened and analyzed for effects on luciferase activity using the HTS.
Compoundswere scored for percent effect relative to the positive control
Tn (Figure 2A). In total, the primary screen identified 117 compounds
with at least a 40% enhancement of luciferase activity.
These compounds were further analyzed in D54-LucT cells, a
control cell line expressing the LucT (luciferase without the ER
translation sequence), which serves as a secondary screen to identify
false-positive luciferase activators. The ratio of luciferase activity in
each screen (ERLucT/LucT) for the 117 compounds is presented
in Figure 2B and shows that 11 of the compounds demonstrated
Figure 1. Optimization of a bioluminescent HTS to detect changes in N-linked glycosylation. (A) Schematic demonstrating the principle
for signal detection using the ERLucT reporter vector: Luciferase is translated into the ER, glycosylated, and inactivated. However, when
ER function is disrupted, the luciferase retains bioluminescent activity. (B) DMSO concentration-activity relationship in the D54-ERLucT
cell line; representative experiment showing average of eight wells per DMSO concentration. (C) Cell density optimization for 96-well
plate format using 1 μM of the GlcNac-phosphotransferase inhibitor Tn; representative experiment showing average of eight wells per
treatment. (D) Dose response of Tn under optimized conditions. Data represent average of eight wells per Tn dose. Tn activates lucif-
erase activity with a half-maximal effective concentration of 40 nM.
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an activation ratio greater than 20-fold. This activation profile
suggested preferential activity in the ER compartment and was thus
identified as HTS “hits.” One of these compounds, Acm, a glyco-
sylated antibiotic and antitumor drug, showed among the highest in-
creases in luminescence in the primary screen as well as the primary
screen/counterscreen ratio (Figure 2, A and B, circles), and a literature
search suggested that Acm may disrupt NLG [22]. On the basis of
the ER-specific effect in the tiered screen, Acm was selected for fur-
ther investigation in both cell-based and biochemical analyses.
Acm Reduces Cell Surface Glycoprotein Expression
Acm preferentially activated the ERLucT reporter, similar to Tn,
and we therefore investigated whether this compound is an NLG in-
hibitor using tertiary analyses. Inhibition of NLG with Tn produces
molecular weight changes and increased protein migration on acryl-
amide gels, and we therefore performed Western blots to examine
the effect of Acm on luciferase Western blot migration (Figure 3A,
top panel ). Unlike Tn, Acm did not increase the gel mobility, suggest-
ing that it did not prevent addition of N-linked glycans to the protein.
Precipitation of protein lysates with the lectin Con A, a maneuver that
removes glycosylated proteins from the lysate, was also performed to
confirm that luciferase remained glycosylated after Acm treatment.
One paradoxical class of compounds that affect luciferase-based
HTSs is luciferase inhibitors [23,24]. In cell-based luciferase assays,
luciferase inhibitors sequester and stabilize luciferase, increase the
amount of protein, and generate a false-positive signal. Acm-treated
cells appeared to have subtle increases in luciferase protein expression
(Figure 3A), and thus to test whether Acm is a luciferase inhibitor,
we determined whether this compound could block luciferase activity
in a cell-free assay using luciferase from crude cell lysates. The results
show that preincubation with resveratrol, a known luciferase inhibitor
[25], significantly reduced the luminescence of our CHO ERLucT
crude lysates (P < .0001) with a mean reduction of 90.4%. However,
preincubation with Acm did not reduce luminescence, eliminating
luciferase inhibition as the mechanism for activity (Figure 3B).
Because Acm has been previously linked with protein NLG [21],
we next investigated its effects on LLO synthesis, as deficiencies in
these enzymatic steps could yield either hypoglycosylation or abnor-
mal transfer of truncated glycan precursors. The effects of Acm on
extracellular glycan expression were first evaluated through adaptation
of a lectin selection assay to a 96-well plate format [26]. The premise
of this positive growth selection assay is that defects late in the ER
LLO synthesis pathway provide a survival advantage when cells are
treated with a combination of the mannosidase inhibitor Sw and
the lectin Con A. This effect is demonstrated in Figure 3C , where
dolichyl-phosphate mannosyltransferase polypeptide 2–defective
CHO cells that do not synthesize the mature 14-carbohydrate LLO
demonstrate significantly increased survival after Sw + Con A treat-
ment (P < .01) relative to equivalently treated parental CHO cells.
We therefore used this strategy to test whether Acm could protect cells
from Con A–dependent toxicity. The results show that Acm does not
protect D54 cells from Sw + Con A toxicity, suggesting that Acm does
not alter biosynthesis of mature LLO species. However, this assay did
show a significant reduction of D54 cell killing by Con A after Acm
treatment (Figure 3C ,middle and right panels; P < .05), a test sensitive
to the general state of surface glycosylation, suggesting that Acm does
reduce cell surface expression of glycosylated proteins.
To confirm that glycan precursor biosynthesis was not reduced by
Acm, we performed direct analysis of LLOs with fluorophore-assisted
carbohydrate electrophoresis (FACE; Figure 3D). Our results show
that pretreatment with Tn reduced synthesis of the mature 14-sugar
LLO in D54-ERLucT cells; however, no change in the abundance
of this LLO species was observed on pretreatment with Acm (or
with three additional screen hits), providing direct biochemical evi-
dence that Acm does not inhibit synthesis of LLOs in these cells.
Taken together, these experiments provide clear evidence that Acm
does not affect protein glycosylation through glycan transfer to ER
Figure 2. HTS of NCI compound libraries. (A) Primary screens of 2802 compounds from the NCI Diversity, Mechanistic, and Natural
Compound libraries were screened at 10 μM using the D54-ERLucT cell line. The activity of each compound relative to Tn is plotted.
(B) Secondary screen of 117 compounds in the D54-LucT cell line, a false-positive screen for nonspecific luciferase activators. Y-axis
represents the ratio of primary/secondary screen activity (ERLucT/LucT ratio). Acm is circled in A and B.
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proteins or by causing aberrant glycosylation through inhibition of
mature LLO biosynthesis.
Acm Reduces RTK Protein Levels
Though our data show that Acm does not block NLG, the HTS
did demonstrate an ER pathway–specific effect and the lectin selection
assay did suggest that Acm reduces cell surface expression of glycosy-
lated proteins. We therefore tested whether Acm could alter ER pro-
teins important for tumor cell survival and analyzed protein levels for
RTKs, a class of ER-dependent proteins that require folding and pro-
cessing in the ER to function. In the D54 glioma cell line, Western
blot analysis demonstrated that, like Tn [17], Acm reduced EGFR
and Met protein levels (Figure 4A). However, Acm did not induce
the Grp78/Bip expression characteristic of NLG inhibition and ER
stress, further demonstrating that Tn and Acm have distinct ER/secretory
pathway targets. The effects of Acm on RTK protein levels were also
tested in the EGFR-amplified and exon 19 kinase domain mutant–
expressing HCC827 lung adenocarcinoma cell line. Treating HCC827
cells with Acm reduced total EGFR and Met protein levels in this cell
Figure 3. Acm does not prevent N-linked glycosylation. (A) Western blot analysis of luciferase size and quantity following incubation with
10 μM of compounds identified in the HTS (top panel). Parallel lysates were also depleted of glycosylated proteins through precipitation
with the lectin Con A agarose. Tn was used as a positive control. (B) Activity of Acm (10 μM) in cell-free luciferase assays compared to
resveratrol, a known luciferase inhibitor and false positive in cell-based luciferase assays. Data represent average of three independent
measurements for each treatment. (C) Lectin-positive growth selection assays. MTT assays were performed in 96-well plates for wild-
type CHO and the glycosylation-defective Lec15 CHO cell line with combinations of 2 μg/ml of the mannosidase inhibitor Sw and 12.5 μg/ml
Con A (left panel). Data represent an average of three wells per treatment. D54 cells were grown under identical conditions with or without
25 nM Acm and treated with Sw, Con A, or a combination of the two (middle panel). Data represent three wells per treatment. Using
the samemethods, D54 cells were incubatedwith increasing concentrations of Con A either with or without Acm pretreatment (right panel).
(D) FACE was performed to determine the levels and composition of LLOs extracted from D54 cultures pretreated with 10 μM of each
compound for 6 hours. Tn (1 μM) was used as a positive control. The mature 14-carbohydrate LLO (Glc3Man9GlcNAc2) is identified with
an arrowhead. An oligosaccharide ladder (left) and a glucose-4 standard (right) provide molecular weight standards.
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line as well without an observed increase in Grp78/Bip expression
(Figure 4B).
Acm Accumulates in the ER
To more clearly identify the relationship between the cellular
effects of Acm and the ER, we directly observed Acm distribu-
tion in live cell cultures. Acm is a fluorescent molecule with two
major emission peaks in the green wavelength range [27], and we
therefore examined Acm cellular localization in two lung adeno-
carcinoma cell lines using fluorescence microscopy (Figure 5). Acm
accumulates in a perinuclear cellular compartment and is excluded
from the nucleus in both the HCC827 and HCC2935 cell lines. To
determine if Acm was accumulating in the ER, we co-treated cell
cultures with an ER-Tracker dye and observed co-localization, sug-
gesting that Acm at least partially accumulates in the ER and post-ER
cellular compartments.
Acm Radiosensitizes EGFR-Mutant Cell Lines
Because Acm treatment reduced RTK protein levels, we hypothe-
sized that Acm would radiosensitize tumor cells that are dependent on
RTK signaling pathways for survival. To test this hypothesis, we inves-
tigated the consequences of Acm treatment in EGFR-dependent lung
adenocarcinoma cell lines (HCC827 and HCC2935). We found that
pretreatment with 500 nM Acm for 2 hours before radiation signifi-
cantly reduced clonogenic survival after radiation at 4 and 6 Gy for
both cell lines (P < .05 and P < .001, respectively). The calculated dose
enhancement ratio at 10% survival was 1.4 for HCC827 and 1.3 for
HCC2935 (Figure 6, A and B). To confirm that RTK signaling was
essential to Acm’s radiosensitizing effect in these cells, we tested A549
lung carcinoma cells. A549 cells carry a G12S activating mutation in
KRAS and are resistant to EGFR-targeted therapeutics [28]. In con-
trast to the RTK-addicted lung lines, we observed no difference in sur-
vival between Acm-treated and untreated A549 cells (Figure 6C ).
Together, these data suggest that Acm disrupts ER function, reduces
RTK protein levels, and enhances radiosensitivity.
Discussion
In this work, we have devised an optimized cell-based assay for
screening small molecule compounds in high-throughput format.
Figure 4. Acm reduces RTK protein levels. (A) D54 cells were
treated with 10 μM Acm (A) or 1 μM Tn (T) for 24 hours, and pro-
tein levels of EGFR, Met, and Grp78 were evaluated with Western
blots. (B) The effects of Acm A on RTK protein levels were analyzed
in the HCC827 cell line using identical conditions. Blots are rep-
resentative of three independent experiments. HSP70 was used
as a loading control.
Figure 5. Localization of Acm in NSCLC. HCC2935 and HCC827 were treated with or without 10 μM Acm for 24 hours followed by
incubation with ER-Tracker Blue-White DPX dye to observe co-localization. Cells were observed using an EVOS-FL digital inverted
microscope, and merged images were created using the EVOS-FL on-board software. Images were captured using a ×40 objective.
Scale bar represents 100 μM.
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The HTS employs a modified luciferase that is designed to lose activ-
ity under normal cell growth conditions and to gain activity when ER
function is compromised. Combined with methods for sensitive de-
tection of luciferase activity, the ERLucT HTS demonstrated a robust
signal-to-noise ratio in microplate formats with statistically significant
predictive power for identifying “hits” and thus provides a novel
method for identifying compounds that preferentially disrupt biologic
functions of the ER in tumor cell lines. To test performance of the
HTS, we used NCI chemical libraries formulated to represent chem-
ical diversity from both synthetic and natural compound sources.
These libraries have previously been shown to be vital research tools,
having been screened to identify modulators of posttranslational pro-
tein modification [29], proteasome function [30], and major devel-
opmental signal transduction pathways [31]. We found that our
ERLucT assay successfully triaged the vast majority of compounds
in the chemical libraries that were tested, validating its use as a primary
HTS and the initial step in a tiered strategy for selecting compounds
with ER-specific functions.
To advance the findings from the ERLucT primary screen, we also
established a secondary cell-based screen in D54 cells that expresses
luciferase without the N-terminal ER translation leader sequence.
This assay served as a screen for false positives and was a practical
method for eliminating compounds that nonspecifically enhanced
luciferase activity in the D54 cell line. Although this secondary screen
was effective for selecting and limiting compounds for further bio-
chemical analyses, we found that it was not sufficient for excluding
all false-positive luciferase activators. The addition of a cell-free lucif-
erase assay to identify compounds that directly interact with and
block luciferase activity showed that several HTS hits were in fact
luciferase inhibitors (data not shown), consistent with other pub-
lished work [22,23]. These results suggest that small molecule/
reporter vector interactions vary according to cellular compartment,
and we therefore recommend both cell-based and cell-free assays for
the identification of false-positive reporter activation in HTS designs.
Our HTS design was complemented by a tiered approach for
evaluating hits in tertiary experimental assays. Because one goal of
this screening program is to identify small molecule inhibitors of
N-linked glycosylation, a site-specific posttranslational modification
that is carried out in the ER, we determined the effects of these com-
pounds on NLG. One of the hits in the screen, Acm, was previously
suggested to be a small molecule that could disrupt NLG [21] and
validating this biologic role for Acm was therefore an emphasis of our
work. However, our results demonstrate that Acm does not directly
inhibit either synthesis of glycan precursors or protein glycosylation
in vitro. This disparity is most likely due to differences in the experi-
mental approach; however, our data are consistent with the previously
observed reduction in cell surface glycoprotein activity attributed to
Acm. The assays presented here focused on the end results of proper
NLG and NLG precursor biosynthesis: molecular weight increases of
glycoproteins, cell surface expression of glycoproteins detectable by
lectin binding assays, and interrogation of NLG precursor synthesis
by FACE. Our results show that implementation of this novel primary
HTS, secondary counterscreen, and tertiary glycosylation assays can
both identify inhibitors of N-linked glycosylation and also be used
to rule out compounds that do not affect NLG per se.
Although Acm was excluded as an inhibitor of NLG, it did pro-
duce ER-specific cellular effects in the primary and secondary
screens. Additionally, and somewhat unexpectedly, treatment with
Acm demonstrated a protective effect on Con A–induced cell death,
suggesting that it reduced cell surface expression of glycoproteins.
Furthermore, direct observation of Acm subcellular localization in
living cells demonstrated that this compound accumulates in the
ER and secretory compartments. We have previously hypothesized
that blockade of the ER biosynthetic machinery would reduce pro-
tein levels of RTKs and provide a strategy for therapeutic radio-
sensitization [17,18], and we therefore examined the effects of
Acm on the RTK glycoproteins, EGFR and Met, in both the D54
and HCC8327 cell lines. Our results showed that Acm significantly
reduced protein levels of these transmembrane receptors without a
generalized effect on protein translation. Together, these experimental
Figure 6. Acm radiosensitizes EGFR-mutant lung cancer cell lines.
Clonogenic survival analysis was performed on NSCLC cell lines har-
boring EGFR kinase domain mutations [(A) HCC827 and (B) HCC2935]
or a KRASmutation [(C) A549]. Cells were pretreatedwith (triangles)
or without (circles) 500 nM Acm for 24 hours. Points represent the
average of three experiments performed in triplicate (HCC-2935 and
HCC-827) or two experiments performed in triplicate (A549), and
error bars represent the SEM.
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results provided evidence for a preferential effect of Acm on the ER
and suggest that Acm accumulates in the ER and disrupts protein
levels and cell surface expression of glycoproteins important for cell
survival signaling such as EGFR and Met.
Acmwas a tantalizing compound for study because of its status as an
existing cancer drug. Acm is used primarily in the treatment of refrac-
tory acute myelogenous leukemia (AML) [32], and Acm is known to
cause DNA damage by inhibiting topoisomerases I and II [33] and can
cause DNA damage indirectly by generating reactive oxygen species
(ROS) [34]. In this work, we have demonstrated that in addition to
its role in causing DNA damage, Acm has at least one additional mech-
anism of action and at least part of Acm’s toxicity is mediated by dis-
rupting the function of the ER. However, exactly how Acm disrupts
the ER is as of yet unclear. Acm does not cause a general repression of
translation as non-ER proteins are not affected, including our non-ER
luciferase reporter. There are several remaining possible explanations
that are not mutually exclusive. One explanation is that Acm generates
ROS that have a deleterious effect on the ER or ER proteins and causes
ER stress [35]. Our data suggest that Acm is not simply activating ER
stress pathways, but an ROS-mediated mechanism cannot be excluded.
A second possible explanation is that Acm affects RTK transport
through the ER or indirectly affects transport by disrupting proper
folding and association with chaperone proteins. ER chaperones in-
cluding calreticulin and calnexin are vital for RTK folding and stability
and promote RTK transport through the ER [36]. Consistent with this,
chaperone inhibitors, such as geldanamycin, an inhibitor of HSP90,
have been shown to inhibit folding of ErbB3 within the ER [37]
and destabilize cytoplasmic EGFR [38] and FGFR3 [39]. Thus, Acm
may disrupt RTK-chaperone interactions that are vital for stability
and folding of RTKs at the early stages in their life cycle.
Acm is a glycosylated natural compound antibiotic, and typical for
the NCI libraries, as it has undergone extensive preclinical and
clinical testing in multiple tumor sites, though it has not been
advanced past phase II trials. This compound has also been evaluated
as a potential radiosensitizer in vitro with conflicting results. Acm
pretreatment was shown to radiosensitize a colon cancer cell line
[40,41], although pretreatment did not radiosensitize HeLa cells
[42]. Because we have demonstrated an ER-specific effect of Acm
and a corresponding reduction of RTK proteins, we tested whether
an enhancement in Acm radiosensitivity could be explained by cell
dependence on ER-translated proteins such as RTKs. To perform
these experiments, we used the HCC827 and H2935 EGFR kinase
domain mutant non–small cell lung cancer (NSCLC) cell lines that
are EGFR-dependent and compared them to the KRAS-mutant (and
EGFR-independent) A549 cell line. The results of clonogenic sur-
vival experiments demonstrate that both EGFR-mutant cell lines
were radiosensitized by Acm, but the RAS-mutant cell line was
not. While the effect of Acm on DNA damage is likely a major con-
tributor to the enhancement of radiosensitivity, our findings suggest
that Acm’s effect on ER function can also modify cellular radiation
responses in susceptible tumor cells. Together, these findings support
the hypothesis that disrupting ER function is a feasible strategy to
enhance tumor cell radiosensitivity.
In summary, we report a set of assays using modified luciferase
reporters that can be used successfully in HTSs to identify com-
pounds that preferentially target the ER. The unique design of our
screening strategy allows the identification of a wide range of ER-
targeting compounds, including cancer therapeutics that can be
difficult to assay secondary to cell toxicity. Using this strategy, we
demonstrated that Acm targets the ER but does not affect the N-linked
glycosylation pathway and that Acm radiosensitizes EGFR-mutant
NSCLC cell lines. This implies that drugs targeting the ER may rep-
resent a novel approach to inducing radiosensitivity in cancer cells and
demonstrates one plausible mechanism to identify those drugs through
a succession of tiered screens.
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